Global X Management Company’s Sage Therapeutics SAGE Stock Holding History

Global X Management Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$94K	Buy	603 +179	+42%	+$28.1K	﹤0.01%	1016
2018 Q1	$68K	Buy	424 +106	+33%	+$18K	﹤0.01%	984
2017 Q4	$52K	Buy	318 +73	+30%	+$7.08K	﹤0.01%	913
2017 Q3	$15K	Buy	245 +35	+17%	+$2.75K	﹤0.01%	1086
2017 Q2	$17K	Buy	210 +79	+60%	+$5.71K	﹤0.01%	1180
2017 Q1	$9K	Buy	131 +7	+6%	+$410	﹤0.01%	1158
2016 Q4	$6K	Hold	124	–	–	﹤0.01%	1052
2016 Q3	$6K	Hold	124	–	–	﹤0.01%	1051
2016 Q2	$4K	Buy	+124	New	+$4.13K	﹤0.01%	960

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Global X Management Company's SAGE Position: Q2 2018 in Review

Global X Management Company increased its Sage Therapeutics (SAGE) stake by 42% in Q2 2018, buying an estimated $28.1K and bringing the position to 603 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #1016.

Global X Management Company first reported a position in SAGE in Q2 2016 and has held it in 9 quarters since. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

Global X Management Company held 603 shares of Sage Therapeutics worth $94K as of Q2 2018.
Global X Management Company bought 179 Sage Therapeutics shares in Q2 2018, an estimated $28.1K.
Sage Therapeutics made up ﹤0.01% of Global X Management Company's portfolio in Q2 2018, its #1016 holding.
Global X Management Company first reported a position in Sage Therapeutics in Q2 2016 and has held it in 9 quarters since.
269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.